Metabolic support of patients with myocardial infarction and liver dysfunction

Main Article Content

M. I. Shved
O. A. Prokopovych


The aim – to improve the existing therapeutic programs for patients with myocardial infarction (MI) by differentiated approach to therapy depending on the presence or absence of liver dysfunction.
Materials and methods. 149 patients with acute MI were included to the study – 114 (76.5 %) men and 35 (23.5 %) women of average age 59.9±1.0 years. A comparative clinical-laboratory and instrumental examination was performed in these groups: 107 patients with MI with functional liver disorders (main group) and 42 patients with MI without functional liver disorders (comparison group). For the study of intracardiac hemodynamics, echocardiography was performed in B-mode. 52 patients of main group and 22 patients of comparison group received standard treatment for MI (ACE-inhibitors, β-blockers, clopidogrel and acetylsalicylic acid, anticoagulant therapy, statins). The other 55 patients of main group and 20 patients of comparison group received modified treatment with the addition of the antioxidant
bioflavonoid – quercetin to the standard scheme.
Results and discussion. In the initial condition of patients of main group there are more pronounced violations of central and peripheral hemodynamics which cause the disorders of protein synthesis, detoxification, energetic dysfunction of liver and lipid metabolism. At the same time there is an excessive activation of lipid peroxidation, suppressed activity of enzymes of the antioxidant protection system, deepening of pathological processes in the heart and in the liver. Inclusion of bioflavonoid quercetin to the complex therapy of patients with myocardial infarction provided the improvement of hemodynamic parameters – increased EF by 22.89 % and elimination of diastolic dysfunction, which were accompanied by normalization of clinical and laboratory parameters of liver function disorders – normalization of levels of bilirubin and ALT, GGT, ALP on 14-th day and reduction of LDL-level by 25.61 % after 3 weeks was marked.
Conclusions. Introduction of bioflavonoid quercetin to the complex therapy of patients with MI provided improvement of hemodynamic parameters and restoration of oxidation-reduction equilibrium, reduction of clinical and laboratory manifestations of liver dysfunction and contributed to a significant decrease in the frequency of MI complications development. Restoration of parameters of cardiac hemodynamics, metabolic processes and liver functions provides a significant reduction in the rate of development of acute heart failure by 63.9 %, early post-infarction angina by 22.2 %, rhythm and conduction disorders by 43.6 %.

Article Details


myocardial infarction, systolic function, diastolic function, functional condition of the liver, lipid peroxidation, antioxidant protection, quercetin


Aliavi AL, Kenzhaiev ML, Aliavi BA. Influence of corvival on the inverse left ventricular myocardial dysfunction in patients with acute coronary syndrome with elevation of segment ST. Praktychna anhiolohiia [Practical angiology] 2009;1:55–59. (in Ukr.).

Lutai YaM, Parkhomenko OM, Ryzhkova NA, Havrylenko TI. Effect of therapy with intravenous 5-lipoxygenase inhibitor quercetin on endothelial function, systemic inflammation and oxidative stress in acute myocardial infarction with ST elevation. Zhurnal «Medytsyna nevidkladnikh staniv» [Journal "Medicine of Emergency Conditions"], 1 (72) 2016. (in Ukr.).

Lutai YaM, Parkhomenko OM, Stepura AA, Irkin OI.

Clinical and prognostic value of the results of a sample with flow-dependent vasodilatation in patients with acute coronary syndrome with elevation ST. Zhurnal «Medytsyna nevidkladnikh staniv» [Journal "Medicine of Emergency Conditions"] 2014;3(58). (in Ukr.).

Moibenko OO, Parkhomenko OM. Efficiency of water soluble form of quercetin (Corvitin) in the treatment of acute coronary syndrome with elevation of segment ST. URL: (in Ukr.).

Parkhomenko OM. Metabolic therapy, or cardioprotection in coronary heart disease: outcomes and perspectives. [Ukrainian Medical Journal] 2008;4(66):15–19. (in Ukr.).

Parkhomenko OM, Kozhukhov SN, Lutai YaM. Justification and design of a multicenter, randomized trial PROTECT - study the efficacy and safety of quercetin in patients with acute myocardial infarction. Ukrainskyi kardiolohichnyi zhurnal.[Ukrainian J of Cardioigy] 2016;3:31–36. (in Ukr.).

Parkhomenko OM, Kozhukhov SN. Results of an open-label randomized study on the tolerability and efficacy of corvitin in patients with congestive heart failure and systolic dysfunction of the left ventricle. Likariu-praktyku [Doctor-practitioner] 2014;4(102). (in Ukr.).

Prokopovych OA. Violation of the functional state of the liver and its correction in patients with myocardial infarction: author's abstract. dis ... Candidate honey. Science:14.01.11. DVNZ "Ivano-Frankiv. nats. med. un-t". Ivano-Frankivsk 2012.20p. (in Ukr.).

Shved MI, Prokopovych OA. Treatment of patients with myocardial infarction with violations of the functional state of the liver. Halytskyi likarskyi visnyk [Galician Medicinal Herald] 2011;2:130–134.

Bartekova M, Carnicka S, Ondrejcakova M, Breier A, Rgerova T. Acute treatment with polyphenol quercetin improves postischemic recovery of isolated perfused rat hearts after global ischemia. Can. J. Physiol. Pharmacol. 2010;88:465–471.

Gregory S, Kelly ND. Quercetin. AMR 2011;16:2:172–94

Jin HB, Yang YB, Song YL, Zhang YC, Li YR. Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats. H. Mol. Biol. Rep. 2012;39:11005–11009.

Hicks JJ, Montes-Cortes DH, Cruz-Dominguez MP, Medina-Santillan R, Olivares-Corichi IM. Antioxidants decrease reperfusion induced arrhythmias in myocardial infarction with ST-elevation. Frontiersin Bioscience. 2007;12:2029–2037.

Kwo PY, Cohen SM, Lim JK. ACG Practice Guideline: Evaluation of Abnormal Liver Chemistries. Am. J. Gastroenterol advance online publication. 2017 Jan;112(1):18–35. doi: 10.1038/ajg.2016.517. Epub 2016 Dec 20.

Silber S. Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC). Herz. 2010;35(8):558–564.

Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Europ. Heart. J. 2008;29(23):2909–2945.

Yellon D, Hausenloy D. Myocardial Reperfusion Injury. N. Еngl. J. Med. 2007;357:1121–35.